Health plan formularies lowered barriers to fair access to some drugs, analysis finds; State Prescription Drug Affordability Boards could end up limiting access to Trikafta

Taking stock of the drug industry, from the lab to the medicine chest

November 3, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

APStock STAT+ | Health plan formularies lowered barriers to fair access to some drugs, analysis finds But only 62% of the formularies scored well on a fourth criteria: cost sharing, which is the portion of expenses paid by insured individuals. By Ed Silverman Opinion: State Prescription Drug Affordability Boards could end up limiting access to the life-saving cystic fibrosis medication Trikafta Access to Trikafta is now at risk for several hundred people with cystic fibrosis, thanks to what some might consider to be good intentions. By Gunnar Esiason STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser